Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martin Jimenez M, Nusch A, Sonke GS, De La Cruz Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon D (2022)
Publication Type: Conference contribution
Publication year: 2022
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S194-S194
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2022.03.280
APA:
Neven, P., Fasching, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A.,... Slamon, D. (2022). Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL). In ANNALS OF ONCOLOGY (pp. S194-S194). AMSTERDAM: ELSEVIER.
MLA:
Neven, P., et al. "Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S194-S194.
BibTeX: Download